Shots:
- The global P-III (TROPION-Breast02) trial assessed Datroway vs CT in 644 pts with previously untreated locally recurrent inoperable or metastatic TNBC, regardless of PD-L1 expression, for whom immunotherapy was not an option
- Trial showed Datroway significantly improved OS & PFS vs CT in TNBC pts; data to be presented in a future meeting & shared with global health authorities
- Datroway is being studied in P-III trials: TROPION-Breast03 (±Imfinzi) for Stage I-III TNBC with residual invasive disease post-neoadj. therapy, TROPION-Breast05 (±Imfinzi) as 1L in PD-L1+ metastatic TNBC, & TROPION-Breast04 (+Imfinzi) as neoadj. for Stage II-III TNBC or HR-low, HER2-low/-negative breast cancer
Ref: AstraZeneca | Image: AstraZeneca & Daiichi Sankyo| Press Release
Related News:- Daiichi Sankyo and AstraZeneca Report the US FDA’s sBLA Acceptance of Enhertu Regimen for HER2+ Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
